A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial.

被引：4
|
作者：
Shapiro, J. D.
Siu, L. L.
Zalcberg, J. R.
Moore, M. J.
Ringash, J.
Mittmann, N.
Simes, J.
O'Callaghan, C. J.
Tu, D.
Walters, I. B.
Magoski, N.
Smith, P.
Nomikos, D.
Zhu, L.
Savoie, M.
Virk, S.
El-Tahche, F.
Gill, R.
Price, T. J.
Jonker, D. J.
机构：
[1] Cabrini Hosp, Malvern, Australia
[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Sunnybrook Hlth Sci Ctr, HOPE Res Ctr, Toronto, ON M4N 3M5, Canada
[7] ANZGOG, Camperdown, NSW, Australia
[8] NCIC Clin Trials Grp, Kingston, ON, Canada
[9] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[10] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
[11] Queen Elizabeth Hosp, Woodville, SA 5011, Australia
[12] Ottawa Hosp, Ottawa, ON, Canada
[13] Univ Ottawa, Ottawa, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps163
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS163
引用
收藏
页数：1
相关论文
共 27 条
  • [11] Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)
    Bennouna, J.
    Hiret, S.
    Borg, C.
    Bertaut, A.
    Bouche, O.
    Deplanque, G.
    Francois, E.
    Conroy, T.
    Ghiringhelli, F.
    des Guetz, G.
    Seitz, J-F.
    Artru, P.
    Stanbury, T.
    Charpentier, S.
    Denis, M.
    Adenis, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [12] The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC).
    Jonker, Derek J.
    Nott, Louise M.
    Yoshino, Takayuki
    Li, Chiang
    Gill, Shariene
    Shapiro, Jeremy David
    Ohtsu, Atsushl
    Zalcberg, John Raymond
    Vickers, Michael M.
    Slims, John
    Wei, Alice Chia-Chi
    Mittmann, Nicole
    Magoski, Nadine M.
    Murray, Yvonne
    Tsobanis, Eric
    Tu, Dongsheng
    Kerstein, David
    O'Callaghan, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [13] Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
    Price, Timothy J.
    Peeters, Marc
    Kim, Tae Won
    Li, Jin
    Cascinu, Stefano
    Ruff, Paul
    Suresh, Atilli Satya
    Thomas, Anne
    Tjulandin, Sergei
    Zhang, Kathy
    Murugappan, Swaminathan
    Sidhu, Roger
    LANCET ONCOLOGY, 2014, 15 (06): : 569 - 579
  • [14] Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study
    Pinto, C.
    Orlandi, A.
    Normanno, N.
    Maiello, E.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Pini, S.
    Bergamo, F.
    Tonini, G.
    Avallone, A.
    Latiano, T. P.
    Rosati, G.
    Pazzola, A.
    Ballestrero, A.
    Zaniboni, A.
    Roselli, M.
    Tamberi, S.
    Barone, C. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1390 - S1390
  • [15] Randomized phase II study of duligotuzumab plus FOLFIRI versus cetuximab plus FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Hill, Andrew G.
    Findlay, Michael
    Burge, Matthew
    Jackson, Christopher
    Garcia Alfonso, Pilar
    Samuel, Leslie
    Ganju, Vinod
    Karthaus, Meinolf
    Amatu, Alessio
    Jeffery, Mark
    DiBartolomeo, Maria
    Bridgewater, John
    Coveler, Andrew
    Hidalgo, Manuel
    Kapp, Amy V.
    Sufan, Roxana
    McCall, Bruce
    Penuel, Elicia
    Pirzkall, Andrea
    Tabernero, Josep
    CANCER RESEARCH, 2015, 75
  • [16] Prognostic genomic signatures in patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES study).
    Normanno, Nicola
    Rachiglio, Anna Maria
    Abate, Riziero Esposito
    Orlandi, Armando
    Maiello, Evaristo
    Maglietta, Giuseppe
    Damato, Angela
    Maiello, Monica Rosaria
    Carotenuto, Marianeve
    Calegari, Maria Alessandra
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria Giulia
    Tamberi, Stefano
    Lonardi, Sara
    Avallone, Antonio
    Latiano, Tiziana Pia
    Tamburini, Emiliano
    Barone, Carlo Antonio
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [17] Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)
    Sakai, Daisuke
    Taniguchi, Hiroya
    Sugimoto, Naotoshi
    Tamura, Takao
    Nishina, Tomohiro
    Hara, Hiroki
    Esaki, Taito
    Denda, Tadamichi
    Sakamoto, Takeshi
    Okuda, Hiroyuki
    Satoh, Taroh
    Tsushima, Takahiro
    Makiyama, Akitaka
    Tsuda, Takashi
    Hosokawa, Ayumu
    Kuramochi, Hidekazu
    Tokunaga, Shinya
    Moriwaki, Toshikazu
    Yasui, Hisateru
    Ishida, Hiroyasu
    Tsuji, Akihito
    Otsu, Satoshi
    Shimokawa, Hozumi
    Baba, Eishi
    Sato, Mikio
    Matsumoto, Shigemi
    Ozaki, Yukinori
    Shinozaki, Katsunori
    Tamagawa, Hiroshi
    Goto, Masahiro
    Kadowaki, Shigenori
    Fujii, Hirofumi
    Koh, Yasuhiro
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Kishimoto, Junji
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    EUROPEAN JOURNAL OF CANCER, 2020, 135 : 11 - 21
  • [18] Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) (ERMES study)
    Normanno, Nicola
    Orlandi, Armando
    Maiello, Evaristo
    Rachiglio, Anna Maria
    Maglietta, Giuseppe
    Damato, Angela
    Calegari, Maria Alessandra
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria Giulia
    Tamberi, Stefano
    Lonardi, Sara
    Tonini, Giuseppe
    Rosati, Gerardo
    Latiano, Tiziana Pia
    Tamburini, Emiliano
    Maiello, Monica Rosaria
    Carotenuto, Marianeve
    Barone, Carlo
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [19] Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients
    Stintzing, S.
    Jung, A.
    Rossius, L.
    Modest, D. P.
    von Weikersthal, L. Fischer
    Decker, T.
    Moehler, M.
    Scheithauer, W.
    Kirchner, T.
    Heinemann, V.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S8 - S9
  • [20] Positive hyperselection of sensitizing genomic alterations (GAs) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES)
    Normanno, N.
    Rachiglio, A. M.
    Abate, R. Esposito
    Orlandi, A.
    Maiello, E.
    Maglietta, G.
    Damato, A.
    Maiello, M. R.
    Carotenuto, M.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Tamberi, S.
    Lonardi, S.
    Avallone, A.
    Latiano, T. P.
    Tamburini, E.
    Barone, C. A.
    Pinto, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S52 - S52
123